newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting

  • AEON Biopharma will present data on ABP-450 (prabotulinumtoxinA) at the 2026 American Academy of Neurology Annual Meeting in Chicago from April 18-22, 2026.
  • The poster presentation, titled "Establishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (Botox ® ) to Support Biosimilarity," occurs on Wednesday, April 22, 2026, from 11:45 am to 12:45 pm CT in Session P11.
  • Presenter Chad K. Oh, M.D., Chief Medical Officer of AEON Biopharma, will discuss analytical data showing identical primary amino acid sequences between ABP-450 and the reference product BOTOX ® .
  • Analytical results indicate 93.5%–99.3% peptide sequence coverage across BoNT/A1 and associated accessory proteins with no variant peptides observed across multiple lots.
  • AEON aims to achieve accelerated & full-label U.S. market entry for ABP-450 as a biosimilar to BOTOX ® under the FDA's 351(k) pathway.
  • ABP-450 is the same botulinum toxin complex currently approved for cosmetic use as Jeuveau ® by Evolus, Inc., & is manufactured by Daewoong Pharmaceutical in an FDA-approved facility.
  • ABP-450 holds biosimilar approval in India, Mexico, & the Philippines, while AEON possesses exclusive development & distribution rights for therapeutic indications in the U.S., Canada, the EU, the UK, & other international territories.
  • The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually & represents a significant opportunity for biosimilar competition.